ActiveComparator Group · 1 Intervention: Standard post-discharge surveillance · Intervention Types: Procedure
Screening: ~3 weeks
Reporting: 90 days
Closest Location: Fox Chase Cancer Center - Philadelphia · Philadelphia, PA
2012First Recorded Clinical Trial
2 TrialsResearching Malignancies
76 CompletedClinical Trials
Who is running the clinical trial?
Fox Chase Cancer CenterLead Sponsor
214 Previous Clinical Trials
32,635 Total Patients Enrolled
5 Trials studying Malignancies
2,323 Patients Enrolled for Malignancies
Jason Castellanos, MDPrincipal InvestigatorFox Chase Cancer Center
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a diagnosis of breast cancer that is > 18 years old.
You are able to carry on all pre-disease performance without restriction.
You are scheduled for elective major cancer surgery (as listed in 4.1.
You are scheduled to be brought from your home (or normal living environment) to FCCC on the day of the index surgery (or day prior as scheduled admission) and you are scheduled to be brought to FCCC for surgery.
You are able to carry out work of a light or sedentary nature.
You are able to carry out all activities of daily living but unable to carry out any work activities.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.